Dr. Chi on the TITAN Trial Results in Metastatic Castration-Sensitive Prostate Cancer
Kim N. Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses the results of the phase III TITAN trial, which evaluated apalutamide versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).
Kim N. Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses the results of the phase III TITAN trial, which evaluated apalutamide versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).
The TITAN study was a double-blind, randomized, placebo-controlled, phase III study that compared the addition of apalutamide to standard androgen deprivation therapy (ADT) with placebo/ADT in this patient population. The study included those with both high- and low-volume disease, as well as patients who received prior therapy, including ADT and docetaxel for castration-sensitive disease, Chi explains.
A total 1052 patients were randomized to receive one of the 2 treatments, and the dual primary endpoints were radiographic progression-free survival and overall survival. At the first analysis, results showed that there was a 52% reduction in the risk of disease progression, as well as a 33% reduction in the risk of death. Secondary endpoints also favored apalutamide, and the safety data showed that the experimental treatment was well tolerated, he says.
